Close

Form 8-K PTC THERAPEUTICS, INC. For: Jun 21

Go back to Form 8-K PTC THERAPEUTICS, INC. For: Jun 21

PTC Therapeutics (PTCT) PT Raised to $46 at RBC Capital

June 23, 2022 5:17 AM EDT

RBC Capital analyst Brian Abrahams raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $42.00) while maintaining a Sector Perform rating.

The analyst comments "Following this week's ph.III Study 041 data, we have made updates to our model including increasing from 80% to... More

PTC Therapeutics (PTCT) PT Lowered to $45 at Cowen

June 21, 2022 4:12 PM EDT

Cowen analyst Joseph Thome lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $48.00) while maintaining a Market Perform rating after the company announced results of Translarna's Study 041 this morning.

The analyst commented, "Based on our conversations with management... More

Raymond James Offers Thoughts on PTC Therapeutics (PTCT)

June 21, 2022 2:37 PM EDT

Raymond James analyst Danielle Brill reiterated an Outperform rating and {REMOVEPT} price target on PTC Therapeutics (NASDAQ: PTCT).

The analyst comments "While ITT data should generally outweigh a subgroup analysis, here ITT was not the prespecified primary population of interest (so p-value might be nominal). Its also unclear what biases might exist for patients enrolled in the trial with baseline metrics that precluded them from being... More

Credit Suisse on PTC Therapeutics (PTCT): 'we continue to employ a wait-and-see approach for Translarna in the U.S'

June 21, 2022 1:12 PM EDT

Credit Suisse analyst Judah C. Frommer reiterated a Neutral rating and $51.00 price target on PTC Therapeutics (NASDAQ: PTCT).

The analyst comments "PTC this morning released topline data from Study 041, the companys Ph3 placebo-controlled trial of Translarna in nonsense mutation DMD patients, ahead of the companys presentation at PPMDs... More

JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT), 'Upside Remains on Raised Full EU Approval Outlook'

June 21, 2022 11:34 AM EDT

JPMorgan analyst Eric Joseph reiterated an Overweight rating on PTC Therapeutics (NASDAQ: PTCT)

The analyst comments "On the whole, we view this mornings top-line Study 041 results as a win for Translarna and PTCT shares. While technically failing on the primary endpoint of 6MWD in the primary subgroup population (patients with 300m and 5m supine to stand at baseline; n~185), Translarna demonstrated significant 6MWD benefit over... More

RBC Capital on PTC Therapeutics (PTCT): 'Data Should Be Good Enough for Translarna to Stay on EU Mkt'

June 21, 2022 9:40 AM EDT

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $42.00 price target on PTC Therapeutics (NASDAQ: PTCT)

The analyst comments "This morning, PTCT revealed data from the ph.III confirmatory Study 041 of Translarna in DMD with nonsense mutations, which was... More

PTC Therapeutics (PTCT) Releases Copy of Slide Deck on Trial of Study 041 for Translarna

June 21, 2022 8:37 AM EDT

PTC Therapeutics (NASDAQ: PTCT) disclosed:

As previously announced, PTC Therapeutics, Inc. (the Company) hosted a conference call on June 21, 2022 at 8:00 a.m. eastern time. During this conference call, the Company discussed the top-line results from the placebo-controlled trial of Study 041 for... More